Market Cap | 114.76M | P/E | - | EPS this Y | 30.70% | Ern Qtrly Grth | - |
Income | -108.58M | Forward P/E | -1.80 | EPS next Y | 34.00% | 50D Avg Chg | -11.00% |
Sales | - | PEG | 0.02 | EPS past 5Y | - | 200D Avg Chg | 36.00% |
Dividend | N/A | Price/Book | 0.62 | EPS next 5Y | -75.30% | 52W High Chg | -57.00% |
Recommedations | 1.80 | Quick Ratio | 12.87 | Shares Outstanding | 38.25M | 52W Low Chg | 173.00% |
Insider Own | 33.29% | ROA | -32.44% | Shares Float | 17.13M | Beta | - |
Inst Own | 53.33% | ROE | -56.31% | Shares Shorted/Prior | 3.07M/4.72M | Price | 3.00 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 3,898,750 | Target Price | 10.00 |
Oper. Margin | - | Earnings Date | May 11 | Volume | 542,494 | Change | 1.01% |
Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Credit Suisse | Outperform | Mar 23, 23 |
B of A Securities | Neutral | Nov 2, 21 |
Jefferies | Buy | Nov 2, 21 |
Credit Suisse | Outperform | Nov 2, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
PFIZER INC | 10% Owner 10% Owner | Mar 17 | Buy | 2.76 | 1,811,594 | 4,999,999 | 5,952,263 | 03/21/23 |
Chin Mark | Other Other | Apr 21 | Sell | 3.05 | 1,745,761 | 5,324,571 | 04/25/22 | |
Chin Mark | Director Director | Oct 13 | Buy | 16 | 312,500 | 5,000,000 | 1,745,761 | 10/15/21 |